OR

Browse By

Professor Pamela McCombe

Professor

UQ Centre for Clinical Research
Faculty of Medicine
pamela.mccombe@uq.edu.au
+61 7 334 66017

Overview

Neurologist

Dr McCombe graduated in Medicine from UQ and completed a Science degree for medical students. She then trained as a neurologist in Sydney, at Prince Henry and Prince of Wales Hospitals. She obtained a PhD from the University of Sydney. She obtained experience in Neurophysiology in Cleveland and then returned to UQ as a post-doctoral fellow. She worked for some years as a research fellow in Neuroimmunology and was an NHMRc SRF. Later she resumed clinical practice as a neurologist, and contimued her research as an NHMRC Practitioner Fellow. She is currentlyProfessor and Head of the Royal Brisbane Clinical school in the School of Medicine and Co-head of the Brain and Mental Health Theme at the UQ Centre for Clinical Research.

Research Interests

  • Biomarkers and heterogeneity in ALS
    One of the challenges of ALS is understanding disease heterogeneity. Our work studies the variability of patients by detailed clinical, laboratory and genetic studies, and by identifying biomarkers that are associated with disease. We use a range of techniques including neurophysiology, MRI, metabolic studies, genetic studies, immune markers and biochemical studies including proteomics. We are using this information to analyse whether patients can be assigned into subgroups and to correlated with survival.
  • Inflammatory neuropathy studies
    This is an ongoing study of the immunological basis and genetic basis of acute and chronic inflammatory neuropathy
  • Pregnancy and MS
    This study is exploring the short and long term effects of pregnancy in multiple sclerosis. This includes the clinical effects of pregnancy and the effects on gene expression and methylation
  • Immunology of stroke
    This study involves documenting the immune responses after human stroke and determining the significance of these responses.
  • Neuromuscular disease
    This work is based at the Neuromuscular clinic at Royal Brisbane and Women's Hospital, and involves correlation of genotype and phenotype of inherited neuromuscular disease

Qualifications

  • FRACP
  • PhD, The University of Sydney
  • BSc, The University of Queensland
  • MBBS, The University of Queensland

Publications

View all Publications

Grants

View all Grants

Supervision

  • Defining the Clinical Phenotype of Autoantibody Associated Epilepsy

    Doctor Philosophy

  • Survival and heterogeneity in Motor Neurone Disease

    Doctor Philosophy

  • Studies of Amyotrophic Lateral Sclerosis

    (2022) Master Philosophy

View all Supervision

Publications

Book

  • Autoimmune neurological disease

    Pender, Michael P. and McCombe, Pamela A. Autoimmune neurological disease. Cambridge, United Kingdom: Cambridge University Press, 2009. doi:10.1017/cbo9780511526916

Book Chapter

  • Biofluid biomarkers of amyotrophic lateral sclerosis

    Holdom, Cory J., Steyn, Frederik J., Henderson, Robert D., McCombe, Pamela A., Rogers, Mary-Louise and Ngo, Shyuan T. (2022). Biofluid biomarkers of amyotrophic lateral sclerosis. Neurodegenerative diseases biomarkers: towards translating research to clinical practice. (pp. 263-306) edited by Philip V. Peplow, Bridget Martinez and Thomas A. Gennarelli. New York, United States: Springer . doi: 10.1007/978-1-0716-1712-0_11

  • Sexual dimorphism in the immune system

    McCombe, Pamela A. and Greer, Judith M. (2019). Sexual dimorphism in the immune system. The autoimmune diseases. (pp. 419-428) edited by Noel R. Rose and Ian R. Mackay. London, United Kingdom: Academic Press. doi: 10.1016/B978-0-12-812102-3.00024-5

  • High Caloric diets for amyotrophic lateral sclerosis

    Ngo, Shyuan T., Steyn, Frederik J., McCombe, Pamela A. and Borges, Karin (2015). High Caloric diets for amyotrophic lateral sclerosis. Bioactive nutraceuticals and dietary supplements in neurological and brain disease: prevention and therapy. (pp. 355-361) edited by Ronald Ross Watson and Victor R. Preedy. London, United Kingdom: Academic Press. doi: 10.1016/B978-0-12-411462-3.00036-9

  • Sexual dimorphism in the immune system

    McCombe, Pamela A. and Greer, Judith M. (2014). Sexual dimorphism in the immune system. The Autoimmune Diseases. (pp. 319-328) edited by Ian R. Mackay and Noel R. Rose. San Diego, United States: Academic Press. doi: 10.1016/B978-0-12-384929-8.00024-1

Journal Article

Conference Publication

  • Determinants of Therapeutic Lag in Multiple Sclerosis

    Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Madueno, Sara Eichau, Patti, Francesco, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Sola, Patrizia, Ferraro, Diana, Bergamaschi, Roberto, Cartechini, Elisabetta, Sa, Maria Jose, Boz, Cavit, Grand-Maison, Francois, Lechner-Scott, Jeannette, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo ... Kalincik, Tomas (2020). Determinants of Therapeutic Lag in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

  • Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis

    Kalincik, Tomas, Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, R. M. M., Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Cartechini, Elisabetta, Van Pesch, Vincent, Iuliano, Gerardo, Granella, Franco, Bergamaschi, Roberto, Fernandez Bolanos, Ricardo ... Butzkueven, Helmut (2020). Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

  • Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis

    Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Ayuso, Guillermo Izquierdo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Hupperts, R. M. M., Alroughani, Raed, Boz, Cavit, Shaygannejad, Vijay, Van Pesch, Vincent, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Ramo-Tello, Cristina ... Kalincik, Tomas (2020). Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

  • Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis

    Roos, I., Frascoli, F., Horakova, D., Havrdova, E. Kubala, Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. Jose, Boz, C., Grand'Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D. ... Kalincik, T. (2020). Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis. Conference of MS Research Australia, Melbourne, Australia, 31 October-1 November 2019. London, United Kingdom: Sage Publications.

  • Low dose Rituximab in the treatment of myasthenia gravis

    Chan, Fiona, Swayne, Andrew, Gillis, David, Wong, Richard, Walsh, Michael, Henderson, Robert, McCombe, Pamela and Blum, Stefan (2020). Low dose Rituximab in the treatment of myasthenia gravis. 18th Biennial Clinical Neurophysiology Workshop of the Australian and New Zealand Association of Neurologists, Gold Coast, QLD, Australia, 29 September–2 October 2019. E Park, Shannon, Ireland: Elsevier . doi: 10.1016/j.clinph.2019.11.034

  • Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

    Hartung, H-P, Comi, G., Arnold, D. L., Boyko, A. N., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2020). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). In: Conference of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Singapore, Singapore, (NP60-NP61). 13-15 November 2019.

  • Cladribine: a multicentre Long-term efficacy Biomarker Australian Study (CLOBAS)

    L-Scott, J., Maltby, V., Lydon, A., Monif, M., Kilpatrick, T., Butzkueven, H., Taylor, B., McCombe, P., Hodgkinson, S., Fabis-Pedrini, M., Kermode, A., Barnett, M. and Kalincik, Tomas (2020). Cladribine: a multicentre Long-term efficacy Biomarker Australian Study (CLOBAS). Conference of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Singapore, Singapore, 13-15 November 2019. London, United Kingdom: Sage.

  • Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis

    Hodgkinson, S., Lizak, N., Butler, E., Lechner-Scott, J., Slee, M., McCombe, P., Shaw, C., Skibina, O., Vucic, S., Shuey, N., Barnett, M., Parratt, J., Butzkueven, H., Jack, D., Fabris, J., Kalincik, T. and Jokubaitis, V. G. (2020). Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis. Conference of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Singapore, Singapore, 13-15 November 2019. London, United Kingdom: Sage.

  • Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up

    Pelletier, D., Arnold, D. L., Bass, A. D., Boyko, A. N., Broadley, S., Comi, G., McCombe, P., Montalban, X., Pozzilli, C., Rovira, A., Selmaj, K. W., Singer, B. A., Vermersch, P., Chung, L., Poole, E. and Wray, S. (2020). Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, West Palm Beach, FL, United States, 27-29 February 2020. London, United Kingdom: Sage Publications.

  • Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years

    Celius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D. Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April - 1 May 2020. Philadelphia, PA United States: Lippincott Williams & Wilkins.

  • Aggressive form of multiple sclerosis can be predicted early after disease onset

    Malpas, C. B., Manouchehrinia, A., Sharmin, S., Roos, I., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H. ... Kalincik, T. (2019). Aggressive form of multiple sclerosis can be predicted early after disease onset. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

    Sharmin, S., Lefort, M., Andersen, J., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Butzkueven, H., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F. ... Kalincik, T. (2019). Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, Sep 11-13, 2019. LONDON: SAGE PUBLICATIONS LTD.

  • Determinants of therapeutic lag in relapsing multiple sclerosis

    Roos, I., Frascoli, F., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofr, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. J., Boz, C., Grand'Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D. ... Kalincik, T. (2019). Determinants of therapeutic lag in relapsing multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

    De Brouwer, E., Peeters, L., Becker, T., Altintas, A., Soysal, A., Van Wijmeersch, B., Boz, C., Oreja-Guevara, C., Gobbi, C., Solaro, C., Ramo, C., Spitaleri, D. L., Maimone, D., Aguera-Morales, E., Cartechini, E., Butler, E., Havrdova, E., Patti, F., Granella, F., Grand'Maison, F., Moore, F., Verheul, F., Iuliano, G., Butzkueven, H., Lechner-Scott, J., Kuhle, J., Sanchez Menoyo, J. L., Rojas, J. I., Prevost, J. ... Moreau, Y. (2019). Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Modifiers of the effectiveness of MS immunotherapies

    Kalincik, T., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Cartechini, E., Van Pesch, V., Iuliano, G., Granella, F., Bergamaschi, R., Bolanos, R. F. ... Butzkueven, H. (2019). Modifiers of the effectiveness of MS immunotherapies. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, Sep 11-13, 2019. LONDON: SAGE PUBLICATIONS LTD.

  • Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data

    Bovis, F., Kalincik, T., Lublin, F., Cutter, G., Malpas, C., Horakova, D., Havrdova, E. Kubala, Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Izquierdo, G., Eichau, S., Patti, F., Terzi, M., Grammond, P., Bergamaschi, R., Sola, P., Ferraro, D., Ozakbas, S., Iuliano, G., Boz, C., Hupperts, R., Grand'Maison, F., Oreja-Guevara, C., Van Pesch, V., Cartechini, E. ... Sormani, M. P. (2019). Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Predicting long-term sustained disability progression in multiple sclerosis

    Sharmin, S., Malpas, C., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Hupperts, R., Alroughani, R., Boz, C., Shaygannejad, V., Van Pesch, V., Cartechini, E., Kappos, L., Lechner-Scott, J., Bergamaschi, R., Turkoglu, R., Solaro, C., Ramo-Tello, C. ... Kalincik, T. (2019). Predicting long-term sustained disability progression in multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)

    Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study). 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY.

  • Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study

    Sprenger, T., Lebrun-Frenay, C., Vermersch, P., Park, M. S., Chinchilla, D., McCombe, P., Lincoln, J., Bergsland, N., Dwyer, M., Kappos, L., Cavalier, S., Roesch, N., Guce, M., Poole, E. and Zivadinov, R. (2019). Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study. 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY.

  • Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

    Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse ... Kalincik, Tomas (2019). Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, United States, 4-10 May 2019. Philadelphia, PA, United States: Wolters Kluwer Health.

  • Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

    Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

  • Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study

    Sprenger, Till, Lebrun-Frenay, Christine, Vermersch, Patrick, Park, Min Su, Chinchilla, Dennis, McCombe, Pamela, Lincoln, John, Kappos, Ludwig, Bergsland, Niels, Dwyer, Michael, Cavalier, Steven, Roesch, Nora, Somera-Molina, Kathleen, Poole, Elizabeth and Zivadinov, Robert (2019). Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

  • Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

    McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage.

  • Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)

    Montalban, X., Arnold, D. L., Boyko, A. N., Comi, G., Hartung, H.-P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Scott, T. F., Vieira Alves Leon, S., Chung, L., Daizadeh, N., Afsar, S. and Selmaj, K. W. (2019). Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study). 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)

    Lechner-Scott, Jeannette, Maltby, Vicky, Lyndon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael and Kalincik, Tomas (2019). Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists (ANZAN), Sydney, Australia, May 21-24, 2019. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2019-anzan.119

  • Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years

    Celius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

  • Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data

    McCombe, P., Vukusic, S., Coyle, P. K., Jurgensen, S., Truffinet, P., Benamor, M., Poole, E., Chavin, J. and Chambers, C. (2019). Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data. Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage.

  • Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study)

    Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S., Nakamura, K. and Van Wijmeersch, B. (2018). Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study). 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

  • Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

    Spelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

  • Determinants of MS re-activation after discontinuing therapies

    Husin, H., Wallace, J., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Trojano, M., Grammond, P., Lugaresi, A., Onofrj, M., Ozakbas, S., Butzkueven, H., Sola, P., Ferraro, D., Alroughani, R., Grand'Maison, F., Terzi, M., Lechner-Scott, J., Boz, C., Hupperts, R., Shaygannejad, V., Bergamaschi, R., Pucci, E., Van Pesch, V. ... Kalincik, T. (2018). Determinants of MS re-activation after discontinuing therapies. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

  • Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

    Le, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand'Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Van der Walt, A., Pucci, E., Granella, F., Van Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J. ... Kalincik, T. (2018). Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

  • Early clinical predictors of severe MS

    Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F. ... Kalincik, T. (2018). Early clinical predictors of severe MS. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

  • Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

    Kister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Altintas, Ayse, Hor, Jyh Yung, Al-Harbi, Talal, Boz, Cavit, Bergamaschi, Roberto, Ozakbas, Serkan, Ferraro, Diana, Fragoso, Yara, Laureys, Guy, Soysal, Aysun, Majdinassab, Nastaran, Onofrj, Marco, Pucci, Eugenio, Vucic, Ostoja (Steve), Slee, Mark, Lechner-Scott, Jeannette, Rojas, Juan Ignacio, Burgos, Marcos, Castillo Trivino, Tamara, Reid, Allyson, Rimler, Zoe, McCombe, Pamela, Granella, Franco ... Butzkueven, Helmut (2018). Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles Ca, Apr 21-27, 2018. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

  • Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)

    Van Wijmeersch, B., Vermersch, P., Boyko, A., de Seze, J., Hartung, H. -P., Havrdova, E. Kubala, Inshasi, J. Said, McCombe, P., Montalban, X., Pozzili, C., Melanson, M., Daizadeh, N., Rodriguez, C. and Selmaj, K. (2018). Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16-19 June 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.

  • Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)

    Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

  • Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

    Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

  • Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

    McCombe, Pamela, Boyko, Alexey N., DeSeze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Vermersch, Patrick, Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Annual Scientific Meeting of the Australian-and-New Zealand-Association-of-Neurologists (ANZAN), Darwin Australia, May 29 - June 1 2018. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2018-ANZAN.43

  • Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)

    Inshasi, Jihad Said, Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Vermersch, Patrick and Margolin, David H. (2018). Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study). 3rd Congress of Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS), Dubai, UAE, 24-25 November 2017 . London, United Kingdom : Sage Publications.

  • Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study)

    Oreja-Guevara, C., Alroughani, R., Brassat, D., Boyko, A. N., McCombe, P., Steingo, B., Van Wijmeersch, B., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Vermersch, P. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406

  • Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study)

    Coles, A. J., Boyko, A. N., De Seze, J., Hartung, H-P., Havrdova, E., Inshasi, J. S., McCombe, P., Montalban, X., Pozzilli, C., Selmaj, K. W., Vermersch, P., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Van Wijmeersch, B. (2017). Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406

  • Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

    Kalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Solaro, C., Grand'Maison, F., Hupperts, R., Prevost, J., Sola, P., Ferraro, D., Terzi, M., Butler, E., Slee, M., Kermode, A., Fabis-Pedrini, M., McCombe, P., Barnett, M., Shaw, C., Hodgkinson, S. and Butzkueven, H. (2017). Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406

  • Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants

    Steyn, Frederik J., Restuadi, Restuadi, Ioannides, Zara, Ngo, Shyuan T., McRae, Allan, Wray, Naomi R., Henderson, Robert and McCombe, Pamela (2017). Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: BMJ. doi: 10.1136/jnnp-2017-316074.81

  • Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

    Kalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand'Maison, F., Boz, C., Trojano, M., Van Wijmeersch, B., Pucci, E., Granella, F., Turkoglu, R., Sola, P., Ferraro, D., McCombe, P., Solaro, C., Van Pesch, V., Ozakbas, S., Slee, M. ... Butzkueven, H. (2017). Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404

  • Gelsolin, clusterin and Cd5L are the potential plasma biomarkers of amyotrophic lateral sclerosis with and without cognitive impairment

    Xu, Zhouwei, Lee, Aven, Henderson, Robert and McCombe, Pamela (2017). Gelsolin, clusterin and Cd5L are the potential plasma biomarkers of amyotrophic lateral sclerosis with and without cognitive impairment. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2017-316074.34

  • Hypermetabolism in Motor Neurone Disease Is Associated with a Greater Functional Decline But Not Weight Loss

    Ioannides, Zara A., Ngo, Shyuan T., Henderson, Robert D., McCombe, Pamela A. and Steyn, Frederik J. (2017). Hypermetabolism in Motor Neurone Disease Is Associated with a Greater Functional Decline But Not Weight Loss. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.18

  • Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry

    Spelman, T., Schulz, M., Arora, B., Chung, E., Juneja, P., Walker, R., Verhaeghe, S., Butzkueven, H., Hodgkinson, S., Lechner-Scott, J., McCombe, P., Slee, M., Butler, E., Barnett, M., Skibina, O., Vucic, S., Macdonell, R., Shuey, N., Taylor, B. and Broadley, S. (2017). Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.

  • Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

    Jokubaitis, V. G., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., van der Walt, A., Nguyen, A. -L., Terzi, M., Alroughani, R., Duquette, P., Girard, M., Prat, A., Boz, C., Sola, P., Lugaresi, A., Lechner-Scott, J., Barnett, M., Grand'Maison, F., Grammond, P., Ramo, C., Turkoglu, R., McCombe, P., Hupperts, R., Bolanos, R. Fernandez, Pucci, E., Trojano, M., Granella, F., Spitaleri, D., Van Pesch, V. ... Butzkueven, H. (2017). Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404

  • Pregnancy incidence, therapy exposure and post-partum relapse risk: a 12-year retrospective multicentre analysis

    Jokubaitis, Vilija, Ai-Lan Nguyen,, Kalincik, Tomas, van der Walt, Anneke, Lechner-Scott, Jeannette, Barnett, Michael, McCombe, Pamela, Vucic, Steve, Hodgkinson, Suzanne, Slee, Mark, Skibina, Olga, Shaw, Cameron and Butzkueven, Helmut (2017). Pregnancy incidence, therapy exposure and post-partum relapse risk: a 12-year retrospective multicentre analysis. Progress in MS Research Conference, Sydney, Australia, 11-13 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517734699

  • Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program

    Rog, D., Oh, J., Chambers, C., Hellwig, K., McCombe, P., Otero, S., Margolin, D. H., Daizadeh, N. and Compston, D. A. S. (2017). Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404

  • Risk of secondary progressive multiple sclerosis: a longitudinal study

    Fambiatos, A., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Hupperts, R., Boz, C., Lechner-Scott, J., Pucci, E., Bergamaschi, R., Van Pesch, V., Ozakbas, S., Granella, F., Ramo, C., Turkoglu, R., Iuliano, G., Spitaleri, D. ... Kalincik, T. (2017). Risk of secondary progressive multiple sclerosis: a longitudinal study. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.

  • Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival

    Xu, Zhouwei, Alruwaili, Ashwag, Henderson, Robert and McCombe, Pamela (2017). Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, QLD, Australia, 9-12 May 2017. London, United Kingdom: BMJ Group. doi: 10.1136/jnnp-2017-316074.29

  • The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis

    Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Prat, A., Girard, M., Hupperts, R., Van Pesch, V., Ferraro, D., Alroughani, R., Bergamaschi, R., Pucci, E., Iuliano, G., Lechner-Scott, J., Spelman, T., Jokubaitis, V., Ramo-Tello, C., Spitaleri, D., Granella, F., Solaro, C., Ampapa, R., Deri, N., McCombe, P., Petersen, T., Van Wijmeersch, B., Prevost, J., Sanchez-Menoyo, J. L. ... Robsertson, N. (2017). The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283

  • The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body composition

    Ioannides, Zara A., Steyn, Frederik J., Henderson, Robert D., McCombe, Pamela A. and Ngo, Shyuan T. (2017). The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body composition. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2017-316074.35

  • The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

    Brown, J. W. L., Lugaresi, A., Horakova, D., Havrdova, E., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Min, M., Shaw, C., Shuey, N., Slee, M., Mccombe, P., Van Pesch, V., Van Wijmeersch, B., Prevost, J., Moore, F., Prat, A., Girard, M., Duquette, P., Ayrignac, X., Sempere, A. Perez, Sanchez-Menoyo, J. L., Ramo-Tello, C., Csepany, T., Hutchinson, M., De Luca, G., Bergamaschi, R., Granella, F., Curti, E. ... Kalincik, T. (2017). The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517733228

  • Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

    Merkel, Bernd, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pamela, Slee, Mark, Vucic, Steve, Skibina, Olga, Barnett, Michael, Hodgkinson, Suzanne, Butzkueven, Helmut and Kalincik, Tomas (2017). Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.16

  • Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

    Merkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Van Pesch, V., Grand'Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C. ... Kalincik, T. (2017). Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283

  • Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study

    McCombe, P. A., Hartung, H-P, Havrdova, E., Selmaj, K. W., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.

    McCombe, P., Achiron, A., Chambers, C., Fox, E. J., Otero, S., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

    Coles, A. J., Boyko, A. N., Cohen, J. A., De Seze, J., Fox, E. J., Havrdova, E., Hartung, H. -P., Inshasi, J. S., McCombe, P., Selmaj, K. W., Vermersch, P., Van Wijmeersch, B., Margolin, D. H., Thangavelu, K., Rodriguez, C. E. and Montalban, X. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Australian cladribine experience

    Kalincik, T., Lizak, N., Jokubaitis, V., Butler, E., Lechner-Scott, J., Slee, M., McCombe, P., Shaw, C., Skibina, O., Vucic, S., Shuey, N., Barnett, M., Parratt, J., Butzkueven, H. and Hodgkinson, S. (2016). Australian cladribine experience. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

    Kalincik, T., Brown, J. W., Robertson, N., Willis, M., Scolding, N., Pearson, O., Ziemssen, T., Hutchinson, M., McGuigan, C., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Alroughani, R., Pucci, E., Sola, P., Hupperts, R., Lechner-Scott, J., Fernandez Bolanos, R., Terzi, M., Van Pesch, V., Rozsa, C. ... Coles, A. (2016). Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)

    Oreja-Guevara, C., Alroughani, R., Brassat, D., Boyko, A. N., McCombe, P., Steingo, B., Van Wijmeersch, B., Margolin, D. H., Thangavelu, K., Rodriguez, C. E. and Vermersch, P. (2016). Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up). 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Individual response to disease modifying therapies: a global observational cohort study

    Kalincik, T., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Girard, M., Prat, A., Duquette, P., Grammond, P., Sola, P., Hupperts, R., Grand'Maison, F., Pucci, E., Boz, C., Alroughani, R., Van Pesch, V., Lechner-Scott, J., Terzi, M., Bergamaschi, R., Iuliano, G., Granella, F., Spitaleri, D., Shaygannejad, V., Oreja-Guevara, C., Slee, M. ... Butzkueven, H. (2016). Individual response to disease modifying therapies: a global observational cohort study. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Pregnancy Outcomes in Alemtuzumab-Treated Patients with Rrms

    Rog, David, Chambers, Christina, McCombe, Pamela, Otero, Susana, Hellwig, Kerstin, Margolin, David, Thangavelu, Karthinathan and Oh, Jiwon (2016). Pregnancy Outcomes in Alemtuzumab-Treated Patients with Rrms. Annual Meeting of the Association-of-British-Neurologists (ABN), Brighton, England, May 17-19, 2016. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2016-315106.155

  • Pregnancy protects against long-term disability accrual in relapsing-remitting MS

    Jokubaitis, V. G., Kalincik, T., Lorscheider, J., Spelman, T., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., Grammond, P., Pucci, E., Grand'Maison, F., Granella, F., Sola, P., Bergamaschi, R., Iuliano, G., Spitaleri, D., Hodgkinson, S., Olascoaga, J., Verheul, F., McCombe, P., Rozsa, C., Lechner-Scott, J., Terzi, M., Hughes, S., Saladino, M. -L., Lugaresi, A., Trojano, M. and Butzkueven, H. (2016). Pregnancy protects against long-term disability accrual in relapsing-remitting MS. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD.

  • Defining secondary progressive multiple sclerosis

    Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pam, Vucic, Steve, Barnett, Michael, Butzkueven, Helmut and Kalincik, Tomas (2015). Defining secondary progressive multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne Australia, Oct 29-30, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

    Jokubaitis, V. G., Spelman, T., Kalincik, T., Travaglini, D., Paolicelli, D., Duquette, P., Girard, M., Prat, A., Havrdova, E., Horakova, D., Izquierdo, G., Grammond, P., Pucci, E., Grand'Maison, F., Bergamaschi, R., Granella, F., Van Pesch, V., Hupperts, R., Iuliano, G., Spitaleri, D., Sola, P., Boz, C., Fernandez-Bolanos, R., Petersen, T., Verheul, F., Olascoaga, J., McCombe, P., Rozsa, C., Lechner-Scott, J. ... Trojano, M. (2015). 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Defining secondary progressive multiple sclerosis

    Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Prat, A., Lugaresi, A., Grand'Maison, F., Grammond, P., Hupperts, R., Alroughani, R., Sola, P., Boz, C., Terzi, M., Pucci, E., Lechner-Scott, J., Bergamaschi, R., Oreja-Guevara, C., Iuliano, G., Van Pesch, V., Bolanos, R. Fernandez, Granella, F., Rio, M. E., Ramo, C. ... Kalincik, T. (2015). Defining secondary progressive multiple sclerosis. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

    Stewart, T., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Prat, A., Lugaresi, A., Grammond, P., Grand'Maison, F., Sola, P., Hupperts, R., Petersen, T., Pucci, E., Bergamaschi, R., Boz, C., Oreja-Guevara, C., Lechner-Scott, J., Alroughani, R., Ramo, C., Van Pesch, V., Fernandez-Bolanos, R., Iuliano, G., Rio, M. E., Granella, F., Slee, M. ... Kalincik, T. (2015). Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program

    Achiron, A., Chambers, C., Fox, E. J., Mc Combe, P., Otero, S., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2015). Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona Spain, Oct 07-10, 2015. LONDON: SAGE PUBLICATIONS LTD.

  • Contribution of various relapse phenotypes to disability in multiple sclerosis

    Kalincik, Tomas, Stewart, Tamasine, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, Slee, Mark, Hodgkinson, Suzanne, McCombe, Pamela, Barnett, Michael, Vucic, Steve, Shuey, Neil, Shaw, Cameron and Butzkueven, Helmut (2015). Contribution of various relapse phenotypes to disability in multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne, Australia, Oct 29-30, 2015. London, United Kingdom: Sage Publications. doi: 10.1177/1352458515616527

  • First-line injectable therapy and pregnancy protect against long-term disability accrual in patients with relapse-onset multiple sclerosis

    Jokubaitis, Vilija, Spelman, Tim, Kalincik, Tomask, Lorscheider, Johannes, McCombe, Pamela, Lechner-Scott, Jeannette, Hodgkinson, Suzanne and Butzkueven, Helmut (2015). First-line injectable therapy and pregnancy protect against long-term disability accrual in patients with relapse-onset multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne, Australia, Oct 29-30, 2015. London, United Kingdom: Sage Publications. doi: 10.1177/1352458515616527

  • Peripheral immune complement activation in neurodegenerative disease

    Mantovani, S., Gordon, R., Ngo, S., Pfluger, C., O'Sullivan, J., Noakes, P., Henderson, R., McCombe, P. and Woodruff, T. (2015). Peripheral immune complement activation in neurodegenerative disease. 25th Biennial Meeting of the International-Society-for-Neurochemistry Jointly with the 13th Meeting of the Asian-Pacific-Society-for-Neurochemistry in Conjunction with the 35th Meeting of the Australasian-Neuroscience-Society, Cairns Australia, 23-27 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/jnc.13188

  • Pregnancy outcomes in the alemtuzumab MS clinical development program

    McCombe, P., Achiron, A., Brinar, V., Margolin, D. H., Palmer, J., Oyuela, P. and Compston, D. A. S. (2015). Pregnancy outcomes in the alemtuzumab MS clinical development program. Pactrims Invited Lecture, Unknown, Unknown. London, United Kingdom: Sage Publications. doi: 10.1177/1352458514563659

  • The missing brain glutamate transporters: what we missed and how this changes our understanding of the excitable brain

    Pow, D., Lee, A., Klinkradt, S., Balcar, V. and McCombe, P. (2015). The missing brain glutamate transporters: what we missed and how this changes our understanding of the excitable brain. 25th Biennial Meeting of the International Society for Neurochemistry Jointly with the 13th Meeting of the Asian Pacific Society for Neurochemistry in Conjunction with the 35th Meeting of the Australasian Neuroscience Society, Cairns, QLD Australia Conference, 23-27 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/jnc.13185

  • Cardiac effects of high-dose fingolimod ingestion

    Sheikh, Nabeel, McCombe, Pamela and Blum, Stefan (2014). Cardiac effects of high-dose fingolimod ingestion. ANZAN Annual Scientific Meeting 2014, Adelaide, South Australia, Australia, May 2014. Elsevier. doi: 10.1016/j.jocn.2014.06.094

  • Characterization of genetic variants in the NFKBIA promoter region in multiple sclerosis

    Yan, Jun, Greer, Judith, Mccombe, Pamela, Pender, Michael and Consortium, Anzgene (2014). Characterization of genetic variants in the NFKBIA promoter region in multiple sclerosis. 12th International Congress of Neuroimmunology (ISNI), Mainz, Germany, Nov 09-13, 2014. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.jneuroim.2014.08.141

  • Killer immunoglobulin-like receptors and their HLA ligands in Guillain-Barré syndrome

    Blum, Stefan, Csurhes, Peter, Reddel, Stephen, Spies, Judy and McCombe, Pamela (2014). Killer immunoglobulin-like receptors and their HLA ligands in Guillain-Barré syndrome. ANZAN Annual Scientific Meeting 2014, Adelaide, South Australia, Australia, May 2014. Elsevier. doi: 10.1016/j.jocn.2014.06.032

  • Gene expression in the spinal cord in MBP-EAE in pregnant and post-partum rats: implications for the effects of MS in pregnancy

    Inglis, H., Greer, J. and McCombe, P. (2012). Gene expression in the spinal cord in MBP-EAE in pregnant and post-partum rats: implications for the effects of MS in pregnancy. 28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Lyon France, Oct 10-13, 2012. LONDON: SAGE PUBLICATIONS LTD.

  • Changes in the gene expression and splicing in the CNS during pregnancy and post-partum in the rat

    Inglis, H., Narayanan, R., Wallace, R., Greer, J. and McCombe, P. (2012). Changes in the gene expression and splicing in the CNS during pregnancy and post-partum in the rat. Progress in MS Research Conference 2011, Melbourne, VIC, Australia, 26-28 October 2011. London, United Kingdom: Sage Publications.

  • Increased expression of the hypoxia related genes in peripheral blood cells of subjects with acute ischaemic stroke

    McCombe, Pamela, Liu, Jia, Yan, Jun and Greer, Judith (2012). Increased expression of the hypoxia related genes in peripheral blood cells of subjects with acute ischaemic stroke. 11th International Congress of Neuroimmunology (ISNI), Boston MA., United States, 4-8 November 2012. Amsterdam, The Netherlands: Elsevier.

  • Investigation of gene mutations in the NFKBIA promoter region in patients with multiple sclerosis

    Yan, J., Pender, M.P., Liu, J., McCombe, P.A., Greer, J.M. and ANZgene Consortium (2012). Investigation of gene mutations in the NFKBIA promoter region in patients with multiple sclerosis. Progress in MS Research Conference 2011, Melbourne, VIC, Australia, 26-28 October 2011. London, United Kingdom: Sage Publications.

  • Bayesian Statistical Motor Unit Number Estimation in the Assessment of ALS

    McCombe, Pamela A., Baumann, Fusun, Henderson, Robert and Anthony, Pettitt (2011). Bayesian Statistical Motor Unit Number Estimation in the Assessment of ALS. 63rd Annual Meeting of the American-Academy-of-Neurology, Honolulu, HI, U.S.A., APR 09-16, 2011. Philadelphia, PA, U.S.A.: Lippincott Williams & Wilkins.

  • Comparison of Motor Units Number Estimation by Bayesian Statistical MUNE with Histological Counting of Motor Unit Numbers: Validation of the Method

    McCombe, Pamela, Ngo, Shuyan, Bellingham, Mark, Pettitt, Anthony and Henderson, Robert (2011). Comparison of Motor Units Number Estimation by Bayesian Statistical MUNE with Histological Counting of Motor Unit Numbers: Validation of the Method. 63rd Annual Meeting of the American-Academy-of-Neurology, Honolulu, HI, U.S.A., APR 09-16, 2011. Philadelphia, PA, U.S.A.: Lippincott Williams & Wilkins.

  • Comparison of Motor Units Number Estimation by Bayesian Statistical MUNE with Histological Counting of Motor Unit Numbers: Validation of the Method

    McCombe, P., Ngo, S., Bellingham, M., Pettitt, A. and Henderson, R. (2011). Comparison of Motor Units Number Estimation by Bayesian Statistical MUNE with Histological Counting of Motor Unit Numbers: Validation of the Method. 63rd AAN Annual Meeting, Honolulu, HI, United States, 9-16 April 2011.

  • Comparison of motor unit number estimation by Bayesian statistical MUNE with histological counting of motor unit numbers

    Ngo, S. T., Bellingham, M. C., Pettitt, A. N., Ridall, P. G., Henderson, R. D. and McCombe, P. A. (2011). Comparison of motor unit number estimation by Bayesian statistical MUNE with histological counting of motor unit numbers. 22nd International ALS/MND Symposium, Sydney, Australia, 30 November - 2 December 2011.

  • Estimation of Motor Unit Loss in Amyotrophic Lateral Sclerosis (ALS)

    Ngo, S. T., Baumann, F., Pettitt, A. N., Ridall, P. G., Henderson, R. D., McCombe, P. A. and Bellingham, M. C. (2011). Estimation of Motor Unit Loss in Amyotrophic Lateral Sclerosis (ALS). Australian Neuroscience Society 31st Annual Meeting, Auckland, New Zealand, 31 January -3 February 2011.

  • Pulsatile Growth Hormone Secretion in the SOD1G93A Mouse Model of ALS

    Steyn, F.J., Ngo, S.T., Buckley, A.J., Leong, J.W., Veldhuis, J.D., McCombe, P.A., Chen, C. and Bellingham, M.C. (2011). Pulsatile Growth Hormone Secretion in the SOD1G93A Mouse Model of ALS. Endocrine Society of Australia Annual Scientific Meeting, Perth Convention and Exhibition Centre, Perth, Western Australia, 28-31 August.

  • Pulsatile growth hormone secretion in the SOD1G93A mouse model of ALS resembles growth hormone deficiency in ALS patients

    Ngo, S. T., Steyn, F. J., Buckley, A. J., Leong, J. W., Veldhuis, J. D., Chen, C., McCombe, P. A. and Bellingham, M. C. (2011). Pulsatile growth hormone secretion in the SOD1G93A mouse model of ALS resembles growth hormone deficiency in ALS patients. 22nd International ALS/MND Symposium, Sydney, Australia, 30 November - 2 December 2011.

  • Bayesian Motor Unit Number Estimation in the SOD1G93A mouse

    Ngo, S.T., Bellingham, M.C., Baumann, F., Pettitt, A.N., Ridall, P.G., Henderson, R.D. and McCombe, P.A. (2010). Bayesian Motor Unit Number Estimation in the SOD1G93A mouse. Forum of European Neuroscience, AMSTERDAM NETHERLANDS, 3/7/2010-7/7/2010.

  • Clinical characteristics of Aquaporin 4 auto-antibody positive patients – A case series

    Blum, Stefan, Wong, Richard, Gillis, David, Wilson, Bob, Prain, Kerryn and McCombe, Pamela (2010). Clinical characteristics of Aquaporin 4 auto-antibody positive patients – A case series. ANZAN Annual Scientific Meeting 2014, Adelaide, South Australia, Australia, May 2014. Elsevier. doi: 10.1016/j.jocn.2010.07.067

  • Clinical features of patients with demyelinating neuropathy associated with Anti-MAG antibody

    Kleinschmidt, Grant D., Henderson, Robert D. and McCombe, Pamela (2010). Clinical features of patients with demyelinating neuropathy associated with Anti-MAG antibody. ANZAN Annual Scientific Meeting 2010, -, 2010. Elsevier. doi: 10.1016/j.jocn.2010.07.081

  • Immune response in acute ischaemic stroke

    Badve, Monica S., Yan, J., Hull, R., Henderson, Robert, O’Sullivan, John D., Read, Stephen J., Wong, Andrew A. and McCombe, Pamela (2010). Immune response in acute ischaemic stroke. ANZAN Annual Scientific Meeting 2010, -, 2010. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jocn.2010.07.064

  • Unusual clinical presentations associated with the A3243G mutation

    Blum, Stefan, Robertson, Thomas, Klingberg, Sandra, Henderson, Robert and McCombe, Pamela (2010). Unusual clinical presentations associated with the A3243G mutation. ANZAN Annual Scientific Meeting 2010, -, 2010. Elsevier. doi: 10.1016/j.jocn.2010.07.066

  • Bayesian analysis of the stimulus-response curve

    Ridall, P. G., Pettitt, A. N., McCombe, P. A. and Henderson, R. D. (2009). Bayesian analysis of the stimulus-response curve. 2nd International Symposium on MUNE and QEMG, Utah, United States, 18-20 August 2006. Amsterdam, The Netherlands: Elsevier BV. doi: 10.1016/S1567-424X(08)00004-4

  • Biological basis for motor unit number estimation through Bayesian statistical analysis of the stimulus-response curve

    McCombe, P. A., Henderson, R. D., Ridall, P. G. and Pettitt, A. N. (2009). Biological basis for motor unit number estimation through Bayesian statistical analysis of the stimulus-response curve. 2nd International Symposium on MUNE and QEMG, Utah, United States, 18-20 August 2006. Amsterdam, The Netherlands: Elsevier BV. doi: 10.1016/S1567-424X(08)00003-2

  • Results of Bayesian statistical analysis in normal and ALS subjects

    Henderson, R. D., Ridall, P. G., Pettitt, A. N. and McCombe, P. A. (2009). Results of Bayesian statistical analysis in normal and ALS subjects. 2nd International Symposium on MUNE and QEMG, Utah, United States, 18-20 August 2006. Amsterdam, The Netherlands: Elsevier BV. doi: 10.1016/S1567-424X(08)00005-6

  • Increased population of activated T cells in patients after acute ischemic stroke

    Yan, J., Greer, J. M., Cavanagh, H., Henderson, R., O'Sullivan, J., Read, S., Etherington, K. and McCombe, P. A. (2007). Increased population of activated T cells in patients after acute ischemic stroke. 37th Annual Scientific Meeting of the Australasian Society for Immunology, Sydney, Australia, 2-6 December 2007.

  • HLA-DR2 is associated with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in females, but not males

    McCombe, P. A., Csurhes, P. A., Alizart, M. A. and Greer, J. M. (2005). HLA-DR2 is associated with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in females, but not males. 5th Annual Meeting of the Federation-of-Clinical-Immunology-Society, Boston, MA, U.S.A., 12-16 May 2005. Orlando, Florida: Academic Press.

  • Antibodies to PMP-22 peptides in inflammatory neuropathy

    McCombe, P. A., Sullivan, A. A. and Alizart, M. A. (2002). Antibodies to PMP-22 peptides in inflammatory neuropathy. 10th International Congress on Neuromuscular Diseases, Vancouver BC, Canada, 7-12 July 2002. AMSTERDAM: ELSEVIER SCIENCE BV.

  • Blood T-cell reactivity to gangliosides GM3 and GQ1b is increased in patients with primary progressive multiple sclerosis

    Pender, M. P., Csurhes, P. A., Wolfe, N. P., Cameron, K. D., McCombe, P. A., Greer, J. M. and Good, M. F. (2002). Blood T-cell reactivity to gangliosides GM3 and GQ1b is increased in patients with primary progressive multiple sclerosis. 127th Annual Meeting of the American Neurological Association, New York City, NY, USA, October 12-16 2002. NEW YORK: WILEY-LISS.

  • Multifocal motor neuropathy: Improvement after autologous bone marrow transplantation

    McCombe, P. A., Morton, J. and Saines, N. (2002). Multifocal motor neuropathy: Improvement after autologous bone marrow transplantation. 10th International Congress on Neuromuscular Diseases, Vancouver Canada, 7-12 July 2002. Amsterdam, Netherlands: Elsevier. doi: 10.1016/S0022-510X(02)80013-2

  • T cell responses to gangliosides in patients with inflammatory neuropathy

    McCombe, P. A., Sullivan, A. A., Alizart, M. A., Csurhes, P. A., Greer, J. M. and Pender, M. P. (2002). T cell responses to gangliosides in patients with inflammatory neuropathy. Xth International Congress on Neuromuscular Diseases, Vancouver, Canada, 07-12 Jul 2002. Amsterda, The Netherlands: Elseiver. doi: 10.1016/S0022-510X(02)80069-7

  • Fluctuations in the frequencies of circulating myelin-reactive T cells in healthy subjects and patients with multiple sclerosis

    Pender, M. P., Csurhes, P. A., Greer, J. M., Mowat, P. D., Henderson, R. D., Cameron, K. D., McCombe, P. A. and Good, M. F. (1999). Fluctuations in the frequencies of circulating myelin-reactive T cells in healthy subjects and patients with multiple sclerosis. ECTRIMS/ACTRIMS'99, Basel, Switzerland, 15 - 18 Sept, 1999. Basingstoke, England: Stockton Press.

  • The role of PMP-22 as an autoantigen in GBS and CIDP

    Sullivan, A., Csurhes, P. A., Alizart, M., Pender, M. P. and McCombe, P. A. (1999). The role of PMP-22 as an autoantigen in GBS and CIDP. Royal Brisbane Hospital Health Care Symposium, Westpac Auditorium Bancroft Cen., 21 - 27 Oct, 1999. Brisbane: Royal Brisbane Hospital.

  • The frequency of circulating T cells reactive to PLP184-209 increases prior to MS relapse and development of new MR1 lesions

    Cameron, K. D., Csurhes, P. A., Good, M. F., Greer, J. M., Henderson, R. D., McCombe, P. A., Mowat, P. D. and Pender, M. P. (1998). The frequency of circulating T cells reactive to PLP184-209 increases prior to MS relapse and development of new MR1 lesions. Fifth International Congress of the International Society of Neuroimmunology, Montreal, QC, Canada, 23-27 August 1998. doi: 10.1016/S0165-5728(98)91636-8

  • Cytokine mRNA expression in lymphocytes from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis

    McCombe, P. A., Nickson, I. and Pender, M. P. (1997). Cytokine mRNA expression in lymphocytes from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. -, -, -. Hoboken, NJ, United States: Wiley-Blackwell. doi: 10.1111/j.1750-3639.1997.tb01051.x

  • Early pregnancy factor and experimental autoimmune encephalomyelitis

    McCombe, P. A., Harness, J., Cavanagh, A. C. and Morton, H. (1997). Early pregnancy factor and experimental autoimmune encephalomyelitis. American Neurological Association Annual Meeting, San Diego CA, United States, 28 September - 1 October 1997. Hoboken, NJ, United States: John Wiley & Sons.

  • Decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis

    Pender, M. P., White, C. A. and McCombe, P. A. (1996). Decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis. American Neurological Association Annual Meeting, Miami FL, United States, 13-16 October 1996. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/ana.410400326

  • T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis

    Pender, M. P., Greer, J. M., Csurhes, P. A., Cameron, K. D., McCombe, P. A. and Good, M. F. (1996). T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis. 121st Annual Meeting of the American Neurological Association, Miami, FL, U.S.A., 13-16 October 1996. BOSTON: LITTLE BROWN CO. doi: 10.1002/ana.410400326

  • Reactivity to myelin proteolipid protein in multiple sclerosis patients

    Cameron, K., Csurhes, P., Greer, J., McCombe, P. and Pender, M. (1995). Reactivity to myelin proteolipid protein in multiple sclerosis patients. The 9th International Congress of Immunology, San Francisco, California, USA, 23-29 July 1995. San Francisco, California, USA: American Association of Immunologists and the International Union of Immunological Societies.

  • Chronic relapsing experimental autoimmune encephalomyelitis: Studies of cells from the spinal cord

    McCombe, P. A., Dejersey, J. and Pender, M. P. (1993). Chronic relapsing experimental autoimmune encephalomyelitis: Studies of cells from the spinal cord. Joint Meeting of the Australasian Society for Immunology and Society for Leukocyte Biology, Sydney, NSW, Australia, 1-5 December 1993. Bethesda, MD, United States: Federation of American Societies for Experimental Biology.

  • Flow cytometric analysis of apoptotic T cells isolated from the central nervous system in experimental autoimmune encephalomyelitis

    Tabi, Z., McCombe, P. A. and Pender, M. P. (1993). Flow cytometric analysis of apoptotic T cells isolated from the central nervous system in experimental autoimmune encephalomyelitis. Joint Meeting of the Australasian Society for Immunology and Society for Leukocyte Biology, Sydney, NSW, Australia, 1-5 December 1993. Bethesda, MD, United States: Federation of American Societies for Experimental Biology.

  • Human T cell responses to myelin basic protein isoforms

    McCombe, P. A., Csurhes, P. A., Houghten, R. A., Good, M. F. and Pender, M. P. (1993). Human T cell responses to myelin basic protein isoforms. International Congress on the Regulation of Leukocyte Production and Immune Function held at the Joint Meeting of the Australasian Society for Immunology and Society for Leukocyte Biology, Sydney, New South Wales, Australia, 1-5 December 1993. Bethesda, MD, United States: Federation of American Societies for Experimental Biology.

  • Absence of antimyelin antibodies and serum demyelinating factors in most CIDP patients

    McCombe, P. A., Pollard, J. D. and McLeod, J. G. (1988). Absence of antimyelin antibodies and serum demyelinating factors in most CIDP patients. -, -, -. Richmond, VIC, Australia: Wiley-Blackwell.

  • Immunogenetics of human demyelinating diseases

    Feeney, D. J., Pollard, J. D., Stewart, G. J., Clark, P., McCombe, P., Kirk, R. L. and McLeod, J. G. (1985). Immunogenetics of human demyelinating diseases. -, -, -. Ottawa, Canada: Canadian Medical Association.

  • ALPHA-1 Antitrypsin Phenotypes in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multiple Sclerosis

    McCombe, P. A., Clark, P., Pollard, J. D., Hammond, S. R. and McLeod, J. G. (1984). ALPHA-1 Antitrypsin Phenotypes in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multiple Sclerosis. You have full text access to this content 109th Annual Meeting of the American Neurological Association, Baltimore MD, 7-10 October 1984. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/ana.410160128

  • Repair of ultraviolet irradiation damage in mouse neuroblastoma cells: a model for post mitotic cell repair

    McCombe, P., Lavin, M. F., Campbell, B., Mansbridge, J. N. and Kidson, C. (1975). Repair of ultraviolet irradiation damage in mouse neuroblastoma cells: a model for post mitotic cell repair. Australian Biochemical Society Annual General Meeting, -, -. Kent Town, SA, Australia: Australian Society for Biochemistry and Molecular Biology.

Edited Outputs

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

Completed Supervision

For Media assistance please contact The Office of Marketing and Communications, (07) 3365 1120

Links

ResearcherID: C-9692-2010

ORCID: 0000-0003-2704-8517

Scopus ID: 7006403442

Google Scholar ID:

Personal Profile: Link

Unit Links
Other Media
Social Media

Related Resources

Similar Staff
Researchers in Associated Units
Fields of Research